Utility of Mac-2 Binding Protein Glycosylation Isomer to Evaluate Graft Status After Liver Transplantation
Copyright © 2020 by the American Association for the Study of Liver Diseases..
Mac-2 binding protein glycosylation isomer (M2BPGi) is a novel liver fibrosis biomarker, but there are few studies on M2BPGi in liver transplantation (LT) recipients. This study aimed to evaluate the utility of M2BPGi measurement in LT recipients. We collected the clinicopathological data of 233 patients who underwent a liver biopsy at Kyoto University Hospital after LT between August 2015 and June 2019. The median values of M2BPGi in patients with METAVIR fibrosis stages F0, F1, F2, and ≥F3 were 0.61, 0.76, 1.16, and 1.47, respectively, whereas those in patients with METAVIR necroinflammatory indexes A0, A1, and ≥A2 were 0.53, 1.145, and 2.24, respectively. Spearman rank correlation test suggested that the necroinflammatory index had a stronger correlation to the M2BPGi value than the fibrosis stage. The area under the receiver operating characteristic curve of M2BPGi to predict ≥A1 was 0.75, which was significantly higher than that of any other liver fibrosis and inflammation marker. Patients with a rejection activity index (RAI) of ≥3 had a higher M2BPGi value than those with RAI ≤ 2 (P = 0.001). Patients with hepatitis C virus viremia had a higher M2BPGi value than sustained virological responders or those with other etiologies. In conclusion, the present study demonstrated that M2BPGi values are more strongly influenced by necroinflammatory activity and revealed M2BPGi, which has been thought to be a so-called fibrosis marker, as a disease activity marker in transplant recipients. M2BPGi measurement may be useful to detect early stage liver inflammation that cannot be detected by routine blood examination of LT recipients.
| Errataetall: |
CommentIn: Liver Transpl. 2021 Feb;27(3):327-328. - PMID 33111474 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society - 27(2021), 3 vom: 15. Feb., Seite 403-415 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kimura, Yusuke [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 31.03.2021 Date Revised 09.05.2023 published: Print-Electronic CommentIn: Liver Transpl. 2021 Feb;27(3):327-328. - PMID 33111474 Citation Status MEDLINE |
|---|
| doi: |
10.1002/lt.25870 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM313557705 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM313557705 | ||
| 003 | DE-627 | ||
| 005 | 20231225150831.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/lt.25870 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1045.xml |
| 035 | |a (DE-627)NLM313557705 | ||
| 035 | |a (NLM)32780942 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kimura, Yusuke |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Utility of Mac-2 Binding Protein Glycosylation Isomer to Evaluate Graft Status After Liver Transplantation |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.03.2021 | ||
| 500 | |a Date Revised 09.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Liver Transpl. 2021 Feb;27(3):327-328. - PMID 33111474 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 by the American Association for the Study of Liver Diseases. | ||
| 520 | |a Mac-2 binding protein glycosylation isomer (M2BPGi) is a novel liver fibrosis biomarker, but there are few studies on M2BPGi in liver transplantation (LT) recipients. This study aimed to evaluate the utility of M2BPGi measurement in LT recipients. We collected the clinicopathological data of 233 patients who underwent a liver biopsy at Kyoto University Hospital after LT between August 2015 and June 2019. The median values of M2BPGi in patients with METAVIR fibrosis stages F0, F1, F2, and ≥F3 were 0.61, 0.76, 1.16, and 1.47, respectively, whereas those in patients with METAVIR necroinflammatory indexes A0, A1, and ≥A2 were 0.53, 1.145, and 2.24, respectively. Spearman rank correlation test suggested that the necroinflammatory index had a stronger correlation to the M2BPGi value than the fibrosis stage. The area under the receiver operating characteristic curve of M2BPGi to predict ≥A1 was 0.75, which was significantly higher than that of any other liver fibrosis and inflammation marker. Patients with a rejection activity index (RAI) of ≥3 had a higher M2BPGi value than those with RAI ≤ 2 (P = 0.001). Patients with hepatitis C virus viremia had a higher M2BPGi value than sustained virological responders or those with other etiologies. In conclusion, the present study demonstrated that M2BPGi values are more strongly influenced by necroinflammatory activity and revealed M2BPGi, which has been thought to be a so-called fibrosis marker, as a disease activity marker in transplant recipients. M2BPGi measurement may be useful to detect early stage liver inflammation that cannot be detected by routine blood examination of LT recipients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Membrane Glycoproteins |2 NLM | |
| 700 | 1 | |a Taura, Kojiro |e verfasserin |4 aut | |
| 700 | 1 | |a Hai Nam, Nguyen |e verfasserin |4 aut | |
| 700 | 1 | |a Uemoto, Yusuke |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshino, Kenji |e verfasserin |4 aut | |
| 700 | 1 | |a Ikeno, Yoshinobu |e verfasserin |4 aut | |
| 700 | 1 | |a Okuda, Yukihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Nishio, Takahiro |e verfasserin |4 aut | |
| 700 | 1 | |a Yamamoto, Gen |e verfasserin |4 aut | |
| 700 | 1 | |a Tanabe, Kazutaka |e verfasserin |4 aut | |
| 700 | 1 | |a Koyama, Yukinori |e verfasserin |4 aut | |
| 700 | 1 | |a Anazawa, Takayuki |e verfasserin |4 aut | |
| 700 | 1 | |a Fukumitsu, Ken |e verfasserin |4 aut | |
| 700 | 1 | |a Ito, Takashi |e verfasserin |4 aut | |
| 700 | 1 | |a Yagi, Shintaro |e verfasserin |4 aut | |
| 700 | 1 | |a Kamo, Naoko |e verfasserin |4 aut | |
| 700 | 1 | |a Seo, Satoru |e verfasserin |4 aut | |
| 700 | 1 | |a Iwaisako, Keiko |e verfasserin |4 aut | |
| 700 | 1 | |a Hata, Koichiro |e verfasserin |4 aut | |
| 700 | 1 | |a Imai, Takumi |e verfasserin |4 aut | |
| 700 | 1 | |a Uemoto, Shinji |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society |d 2000 |g 27(2021), 3 vom: 15. Feb., Seite 403-415 |w (DE-627)NLM105775185 |x 1527-6473 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2021 |g number:3 |g day:15 |g month:02 |g pages:403-415 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/lt.25870 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2021 |e 3 |b 15 |c 02 |h 403-415 | ||